Clinical Trial Update: Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy results for the ophthalmic solution R932348 in patients with chronic ocular graft-versus-host disease (DROPS-2) have been completed,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• R932348

Snippet

Sponsor: Rigel Pharmaceuticals | Conditions: Chronic Graft-versus-host Disease | Phase 2 | Status: COMPLETED | Results posted: 2016-10-10